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ABSTRACT:
Neuroblastoma is an aggressive pediatric cancer originating embryonically from
the neural crest. The heterogeneity of the disease, as most solid tumors, complicates
diagnosis and treatment. In neuroblastoma this heterogeneity is well represented
in both primary tumours and derived cell lines and has been shown to be driven by
a population of stem-like tumour initiating cells. Resolving the molecular mediators
driving the division of this population of cells may indicate effective therapeutic
options for neuroblastoma patients. This study has determined that the atypical
cyclin-like protein Spy1, recently indicated in driving symmetric division of glioma
stem cells, is a critical factor in the stem-like properties of neuroblastoma tumor
initiating cell populations. Spy1 activates Cyclin Dependent Kinases (CDK) in a manner
that is unique from classical cyclins. Hence this discovery may represent an important
opportunity to design CDK inhibitor drugs to uniquely target subpopulations of cells
within these aggressive neural tumours.

INTRODUCTION

stage of tumour differentiation and ultimately contribute
to neuroblastoma pathogenesis [9]. Indeed those tumours
with a poorly differentiated phenotype correlate negatively
with clinical outcomes [9, 10]. In addition, self-renewing
tumour initiating cells (TICs) were reported to correlate
with refractory or relapse state following the initial
good response to therapy observed in patients [11]. The
neuroblastoma stem-like TICs were identified among the
heterogeneous population in cultured human cell lines
[12-14]. Interestingly, several groups demonstrated the
three principle populations of neuroblastoma cells: the
highly proliferative yet weakly tumourigenic N-cells,
the crest derived non-neuronal S precursors and the
I-type malignant and multipotent neural crest stem cells
harbouring TIC potential [15]. The I-type cells express
CD133 and c-kit stem cell marker proteins and are capable
of self-renewal and forming rapidly growing tumours [13,
16, 17]. Importantly, the pentaspan protein CD133 was
shown to regulate cell proliferation and differentiation in
neuroblastoma [17]. Proliferation and differentiation are
under control of the cell cycle however what regulates
the balance of these decisions in the three dominant
populations of cells found in neuroblastoma remains to
be determined.

Neuroblastoma is the most common pediatric
extracranial solid malignancy with 98% of patients
diagnosed by the age of 10 [1]. The disease has an
unpredictable clinical course and poor prognosis, with
only 30% long-term survival [1]. Due to its origin in
the migratory neural crest, neuroblastoma occurs in
the peripheral nervous system arising in sympathetic
ganglia and adrenal medulla [2-4]. The neural crest is a
population of stem cells that derives from the neural tube
during embryogenesis. Therefore, the transient embryonic
structure of the tumours is reflected in the enormous
genetic and phenotypic heterogeneity of neuroblastoma.
Although an inherited genetic predisposition was
shown in a small subset of patients, spontaneous genetic
changes are the most frequently observed. This commonly
includes activation of oncogenes like MYCN and H-Ras,
gain or loss of alleles, and alternations in cell ploidy [58]. Neuroblastoma tumours display diverse immature
cell types such as neuroblasts and glial precursors and
an array of heterogeneous cell types at different stages of
differentiation. Accumulating in vitro and in vivo evidence
suggests that alteration in cell cycle control may affect the
www.impactjournals.com/oncoscience
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RESULTS

Spy1 (Spdya; Speedy; Spy1A; RINGO), encoded by
SPDYA gene, is a cell cycle regulator that controls CDK2
activity and G1-S phase transition in a fashion unique
from that established for the classical cyclin proteins. The
Spy1-CDK2 complex does not require CDK activating
kinase (CAK) -mediated phosphorylation on CDK2,
and it is less sensitive to inhibitory phosphorylation by
regulators such as p21Cip1 and p27Kip1 [18-21]. Thus, Spy1
is able to override several known cell cycle checkpoints,
including those imposed by DNA damage [22, 23]. Both
CDK2 and p27Kip1 play an important role in neuroblastoma
progression and patient prognosis [24-26]. Notably, p27Kip1
accumulates in neuroblastoma cells treated with retinoids
and necessitates neuronal differentiation [27], whereas
increased CDK2 activity correlated with a differentiation
blockage [28]. Recently we have shown Spy1 to be an
important factor regulating stemness in the adult brain and
human glioma [29]. Spy1 expression drove expansion of
the glioma population expressing characteristic stem cell
markers including CD133. Spy1 promoted clonality and
suppressed multilineage differentiation potential in human
glioma. Mechanistically, our data demonstrated that Spy1
is an essential driver of symmetric division of the CD133+
population in human glioma. Neuroblastoma TICs share
many of the hallmark characteristics found in glioma [13,
15, 30] and the CD133+ population in neuroblastoma
patient and cell line samples increases clonal expansion
and tumourigenicity [30]. Hence, we sought to determine
if Spy1 plays a driving role in neuroblastoma TIC
populations.
This study investigated the role of Spy1 in
proliferation, self-renewal and differentiation of
human neuroblastoma cell lines. We find that Spy1
overexpression in the N-type neuroblastoma SH-SY5Y
cells results in significantly upregulated proliferation
and resistance to the 13-cis-Retinoic Acid (RA)-induced
differentiation. Interestingly, Spy1 overexpressing cells
demonstrated increased self-renewal in a neurosphere
formation assay and upregulation of markers indicative of
the multipotency. The forced upregulation of Spy1 levels
conferred prolonged clonality and survival to serially
subcultured spheres whereas downregulation of Spy1
levels resulted in decrease in tumorsphere number. Our
data reveals that Spy1 is implicated in regulating CD133+
neuroblastoma cell populations. The obtained data
demonstrates a role for an atypical cell cycle mechanism
in driving tumourigenicity of neural crest stem cells.
Importantly, this mechanism has strong implications in
regulating resistance in at least subsets of neuroblastoma.
Determining how to block the atypical activation of
CDKs may prove a valuable therapeutic direction for
neuroblastoma.

www.impactjournals.com/oncoscience

Endogenous levels of Spy1 are downregulated
during
RA-induced
differentiation
in
neuroblastoma
To determine how Spy1 is expressed through
differentiation in neural progenitor cells human
neuroblastoma SH-SY5Y cells, were induced to
differentiate over several days using RA. Cells were
scored as differentiated when the neurite length exceeded
twice the size of the cell body. Spy1 protein levels were
abruptly depleted upon addition of RA, with levels
being significantly depleted between 16-48 hours postdifferentiation (Fig. 1A). This occurs concurrent with an
upregulation of the differentiation marker GAP43 and a
downregulation of the stemness marker Nestin (Fig. 1A;
lower panel). QRT-PCR analysis upon RA stimulation
revealed that endogenous SPDYA expression levels were
significantly downregulated by 48 hours after the addition
of RA (Fig. 1B). Kinase assays showed that in vitro CDK2
kinase activity declines in parallel with Spy1 expression
levels (Fig. 1C).

Stable overexpression of Spy1 causes delayed
neural differentiation
We tested a panel of neuroblastoma cell lines for
Spy1 protein expression levels (Fig. 2A). It was noted
that SH-SY5Y cells had significantly lower levels of Spy1
than levels found in CHLA15, CHLA20 or BE(2)C cells.
This correlated with protein levels of the oncogene c-Myc,
known to transcriptionally upregulate Spy1 levels [32].
To determine the effect of abnormal elevation of Spy1
protein on differentiation in neuroblastoma, Spy1 or an
empty vector control were stably overexpressed in the
SH-SY5Y cells. SH-SY5Y-WT (expressing empty vector)
and SH-SY5Y-Spy1 (Spy1 overexpressing) cell lines
were induced to differentiate and observed over a 72 hour
time course. By 72 hours post-differentiation over 75%
of control cells successfully differentiated while no signs
of differentiation were visible in the Spy1 overexpressing
cells (Fig. 2B; right panel). To determine whether effects
could be due to the known proliferative effects of Spy1,
cell numbers, BrdU incorporation and PCNA staining was
conducted (Fig. 2D &2E). At 96 hours post-differentiation
SH-SY5Y-Spy1 cells continued to proliferate, while SHSY5Y-WT cells had significantly reduced proliferation,
indicative of terminal differentiation (Fig. 2C). This was
also demonstrated by incorporation of BrdU (Fig. 2D)
and PCNA (Fig. 2E). In each assay Spy1 overexpressing
cells continued to synthesize DNA and cycle at 72 hours
post-differentiation while over 50% of control cells enter
quiescence by 48 hours post-differentiation. Interestingly,
337
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qRT-PCR of cells overexpressing Spy1 in the presence
of differentiation stimuli revealed significantly higher
levels of the neural stem cell (NSC) marker Nestin (Fig.
2F) and significantly lower expression of the neuronal
differentiation marker, growth associated protein 43

(GAP43) (Fig. 2G), than control counterparts.

Spy1 regulates self-renewal in neuroblastoma cells
The pool of multipotent NSCs can be purified from
heterogeneous cell population utilizing a neurosphere
formation assay. Unlike neural progenitor cells with
limited proliferative potential, only highly proliferative
multipotent NSCs can retain the ability to self-renew
and produce neurospheres that can be passaged in a
long term culture [33]. Additionally, neurospheres
derived through this assay retain the capacity to express
GAP43 and glial fibrillary acidic protein (GFAP) upon
differentiation conditions [34]. SH-SY5Y neuroblastoma
cells have been previously shown to express markers of
typical neural crest stem cells [35, 36], and to contain
populations of self-renewing, multipotent tumour cells
[30, 37]. Interestingly, we found that endogenous levels
of Spy1 were significantly elevated in cells cultured
as neurospheres when compared to monolayer culture,
supporting the endogenous requirement for this protein in
maintaining multipotency (Fig. 3A). We investigated the
influence of Spy1 overexpression on self-renewal in SHSY5Y cells cultured as neurospheres. Spy1 overexpressing
cells almost doubled the number of neurospheres as
compared to controls (Fig. 3B). Increases in neurosphere
number were significant for neurospheres of a diameter
smaller than 100µm; however, there was no significant
increases seen for neurospheres larger than 100µm (Fig.
3C), notably cultures were carried out in a flat dish and not
in aggregate culture [38]. Serial passaging of neurospheres
demonstrated that Spy1 overexpressing populations had
enhanced longevity over control neurospheres (Fig. 3D).

Spy1 regulation of stemness and neural lineage
commitment is controlled by extracellular
microenvironment
Figure 1: Spy1 protein levels are tightly regulated
during neuroblastoma progenitor fate decisions. (A)

Given the environmental differences seen with
Spy1 expression in neurosphere culture, corresponding
passages of SH-SY5Y-WT or SH-SY5Y-Spy1 cells were
cultured either in monolayer or as neurospheres and gene
expression was analyzed. Expression of the pluripotency
marker Oct-4 (Fig. 4A) and the stem cell marker BMI1
(Fig. 4B) were significantly elevated by Spy1 when
cultured as neurospheres but not in monolayer culture.
Spy1 expression significantly elevated the expression of
glial progenitors and stem-like TIC markers (Fig. 4C-F).
Specifically, Spy1 enhanced expression of the gene for the
glial progenitor marker OLIG2 (Fig. 4C), the astrocytespecific marker GFAP (Fig. 4E) and the TIC marker
CD133 (Fig. 4F). Spy1 also enhanced expression of the
gene for fibronectin (FN1), which has been shown to
mediate invasiveness and cell survival in other types of
neural derived tumours (Fig. 4D) [39-41].

SH-SY5Y cells differentiated in 13-cis Retinoic Acid (RA)
(2µM) and assayed at the indicated times. Differentiation was
recorded by phase contrast inverted microscopy (upper panel)
and cell lysates were analysed by SDS-PAGE (lower panel).
Neuronal differentiation was confirmed by detection of GAP43
expression. α-Tubulin was used as a loading control. Scale bar,
50 µm. (B) SPDYA expression was assessed over a differentiation
time course in SH-SY5Y cells by qRT-PCR. Vehicle-treated
cells were used as a control. Results are presented as mean ±
s.d. for triplicate samples from a representative experiment. n=4,
**p < 0.01 (Student’s t-test). (C) CDK2 activity was analyzed
at the indicated time points post RA treatment in SH-SY5Y
cells. Vehicle treated cells were used as a control. Phosphorimaging analysis is demonstrated as Density Light Units (DLU)
/mm2 (upper panel). Lower panel depicts a representative
phosphorimage. Results are presented as mean ± s.d of a
representative experiment. n=2, *p < 0.05 (Student’s t-test).
www.impactjournals.com/oncoscience
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Figure 2: Spy1 overexpression abrogates neuronal differentiation of neuroblastoma. (A) A series of neuroblastoma cell lines
probed for Spy1 expression by SDS-PAGE One representative blot of 3 is depicted (left hand panel). Densitometry values are presented
as the mean of Integrated Density Values (IDV) Spy1/Actin over 3 experiments (right panel). *p<0.05. (B-G) SH-SY5Y cell line was
generated by stably expressing flag-tagged Spy1 (SH-SY5Y-Spy1) and empty vector (SH-SY5Y-WT). Cells were differentiated using 2µM
13-cis-Retinoic Acid (RA). (B) Morphology over a time course was documented using inverted phase contrast microscopy (left panel).
Differentiation was scored according to axon length, and the ratio of differentiated cells to total cell number was calculated (right panel).
Control bars (hollow), Spy1 overexpressing (black bars). Values are mean ± s.d. n=3; *p < 0.05, **p < 0.01, ***p < 0.001 (Student’s
t-test). Scale bar, 50 µm. (C) Cells were seeded at the density 0.5 x104 cells/ml and differentiated using 2µM RA. Cells were harvested
and subjected to the trypan blue analysis at indicated times. Representative data are shown as mean ± s.d. n=3, **p < 0.01, ***p < 0.001.
(D) SH-SY5Y cells were subjected to BrdU incorporation along the RA-induced differentiation time course. Immunocytochemistry was
conducted at 48 hours and 72 hours. PI was used as a nuclear counterstain (not shown). Scale bar, 100µm. (E) PCNA negative cells and total
cell number were scored in 3 different fields of view at 48hours and 72hours time points. PCNA negative cells are expressed as a percentage
of total cell number at each time point. Data are shown as mean ± s.d; n=2. (F & G) Expression levels of (F) Nestin and (G) GAP43 were
analyzed by qRT-PCR in SHSY5Y-WT (WT) and SH-SY5Y-Spy1 (Spy1) along differentiation time-course. Representative data are shown
as mean ± s.d. n=3; *p < 0.05 (E) and ***p < 0.001 (F).
www.impactjournals.com/oncoscience
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Depletion of Spy1 in neuroblastoma decreases cell
proliferation and clonality

addressed the role of Spy1 in stemness properties of cell
lines characterized by higher Spy1 protein (Fig. 2A).
Spy1 levels were depleted in heterogeneous populations
of the CHLA-20 and CHLA-15, both shown to contain
high endogenous levels of Spy1 (Fig. 2A). CHLA-20 line
contains a pool of CD133+/CD34+/Nestin+ TICs [30]
and both CHLA-20 and CHLA-15 cell lines are resistant
to conventional chemotherapy [42]. Spy1 knock-down
using two different shRNA constructs caused significant
decrease of CHLA-15 and CHLA-20 cell proliferation
(Fig. 5A, left & right panel respectively) and increase
in the levels of GAP-43 neuronal marker mRNA levels
(Fig. 5B). To determine the role of Spy1 in self-renewal
of these cells we subjected Spy1 knockdown cells to
neurosphere formation assay. A decrease in the number
of spheres formed in both cell lines was noted, although
this was not significant (Fig. 5C, left & right panel). The
downregulation of Spy1 was followed by a significant
decrease in CD133 in both CHLA-15 and CHLA-20 cell
lines, and a significant decline in c-MYC mRNA levels
in CHLA-15 cells (Fig. 5D). These results demonstrate
that Spy1 downregulation is required for neuronal
differentiation to take place in heterogeneous populations
of neuroblastoma cells and support that Spy1 is required

Given the heterogeneity of tumours and reported
populations of cancer stem cells in neuroblastoma we

Figure 3: Elevated levels of Spy1 protein promote
neuroblastoma progenitor self renewal. (A) SH-SY5Y
cells cultured as neurospheres (NS) or in monolayer (ML)
were harvested and SPDYA expression levels determined by
qRT-PCR. Data shown is mean ±s.d, ***p < 0.001. (Student’s
t-test, n=3). (B-D) SH-SY5Y-WT and SH-SY5Y-Spy1 cells
were grown in neurosphere assays. (B) Morphology of cultures
by light microscopy (left panels). Scale bar, 100 µm. Spheres
were passaged every 6-7 days and the neurosphere formation
efficiency was quantified as a number of spheres relative to the
total number of the cells seeded (right panel). Representative
data are shown as mean ±s.d. of triplicates from three
independent experiments, **p < 0.01 (Student’s t-test; n=3).
(C) Neurospheres maintained in culture for 14 days were scored
according to diameter. Values presented as mean ±s.d. of two
independent experiments, **p < 0.01. (Student’s t-test). (D)
Primary, secondary and tertiary neurospheres were subjected to
MTT assay. The obtained absorbance at 590nm was corrected
for background absorbance. Data shown is mean ±s.d, *p < 0.05
(Student’s t-test; n=2).
www.impactjournals.com/oncoscience

Figure 4: Spy1 regulation of stemness and neural
lineage commitment is controlled by extracellular
microenvironment. (A-F) SH-SY5Y control cells (WT) or
overexpressing Spy1 (Spy1), cultured in monolayer (ML) or
as neurospheres (NS). mRNA levels were analysed using qRTPCR. Expression levels of (A) OCT-4, (B) BMI1, (C) OLIG2, (D)
FN1, (E) GFAP, and (F) CD133. Representative data are shown
as mean ±s.d. of triplicates from three independent experiments,
*p < 0.05, **p < 0.01 (Student’s t-test).
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Figure 5: Depletion of Spy1 in neuroblastoma decreases cell proliferation and clonality. (A) Proliferation kinetics of CHLA-

15 (left) and CHLA-20 (right) cells infected with two shRNA constructs against Spy1 (pLKO-shSpy1#1, pLKO-shSpy1#2) or scrambled
control (pLKO-scrambled). (B) GAP-43 expression in pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKO-scrambled CHLA-15 and CHLA-20
cells. (C) Number of neuroblastoma tumorspheres formed by CHLA-15 (left) or CHLA-20 (right) cells infected with pLKO-shSpy1#1,
pLKO-shSpy1#2 or pLKO-scrambled. (D) CD133 (left) and c-MYC (right) expression in pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKOscrambled CHLA-15 and CHLA-20. (A-D) Data is expressed as mean ±s.d. of triplicates from at least three independent experiments, *p
< 0.05, **p < 0.01, ***p<0.001 (Student’s t-test).
www.impactjournals.com/oncoscience
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for maintaining proliferation and aspects of stemness
characteristics in neuroblastoma TICs.

that preventing this downregulation also prevents RAinduced differentiation. Overexpression of Spy1 resulted
in enhanced self-renewal and longevity of neuroblastoma
cells cultured in a neurosphere formation assay. Spy1
levels were also significantly elevated in self-renewing
neurosphere populations, as compared to cells cultured as
a monolayer. Collectively, this suggests a potential role
of the Spy1 protein as a stabilizer of proliferation among
cell populations of higher hierarchy, namely progenitors
and TICs. Spy1 has demonstrated roles in spinal cord
regeneration [47], it was found to possess stem-like
qualities in the developing mammary gland [32] and in
the subventricular zone stem cells in the adult brain [29],
supporting a general role for Spy1 in select populations of
adult stem or progenitor cells.
Spy1 is a direct activator of CDK2 [48], and
Spy1 can indirectly activate CDK2 by promoting the
degradation of the CDK inhibitor p27Kip1 [20]. Dobashi et.
al. demonstrated that a decrease in CDK2 kinase activity
must occur in order to support functional differentiation
[49] and others have demonstrated that p27Kip1 levels
accumulate during neuronal cell differentiation [50].
Interestingly, suppression of CDK2 activity is required for
reduced proliferation and survival of the primary neural
crest derived tumour and its inhibition was demonstrated
to be synthetic lethal in MYCN overexpressing
neuroblastoma [26, 51]. Spy1 direct interactions with
p27Kip1 promote the phosphorylation on Thr-187 of p27Kip1,
a modification that is required for its ubiquitination by
SCFSkp2complex and its subsequent proteolysis [5254]. High expression of the Skp2 component of the
SCFSkp2 ligase was included in the genetic signature of
aggressive stages of neuroblastoma. Skp2 overexpression
correlated with p27Kip1 protein downregulation and poor
patient prognosis [55, 56]. Hence, Spy1-mediated CDK2
activity may affect the outcome of patients with Skp2
overexpression.
We observed a differential effect of Spy1 on
neuroblastoma cells when grown in neurosphere culture,
versus the general population of cells grown in monolayer
culture. In neurosphere culture Spy1-induced expression
of the progenitor and multipotency markers BMI11 and
OCT-4, respectively. Both BMI1 and OCT-4 were shown
to exert their functions in the other neural tumours by
preventing cellular differentiation and contributing
to their growth and progression [57, 58]. Hence, this
data supports the hypothesis that Spy1 may function in
promoting the growth of highly undifferentiated cells in
neuroblastoma. When cells were in monolayer, however,
Spy1 promoted expression of glial progenitors such as
GFAP and OLIG2. SH-SY5Y cells were demonstrated
previously to contain a minute pool of highly clonogenic
S-cells [59] that are also characterized by expression of
glial markers [13]. Thus, forced expression of Spy1 can be
speculated to contribute to the expansion of self-renewing
cell populations within the heterogeneous tumour. We

Clonal properties of CD133+ populations of
neuroblastoma depend on Spy1
To test the hypothesis that Spy1 is involved
in regulating the CD133+ subpopulation within
neuroblastoma, as previously determined in glioma
[29], we sorted CHLA-15 cells for CD133 and subjected
negative and positive populations to neurosphere formation
assays (Fig. 6A). We found no significant difference in the
overall number of the spheres formed between CD133+
and CD133- populations (data not shown), however
CD133+ populations formed significantly more spheres
of a smaller size, while CD133- populations formed larger
spheres (Fig. 6B). When Spy1 expression was driven in
the CD133- population more spheres, particularly of the
smaller size, were formed (Fig. 6C, left panel). Spy1
overexpression in this population correlated with an
increase in the levels of CD133, c-MYC and Ki67, TIC
and proliferation marker levels in CD133- cells (Fig. 6E).
In opposition to this, Spy1 knockdown in CD133+ cells
(Fig. 6C, right panel) resulted in significant decline in
the number of spheres formed (Fig. 6D; right panel) and
decreased expression levels of Ki67 and c-MYC (Fig.6F).
We were not able to amplify CD133 in Spy1 knockdown
CD133+ samples (not shown).
Overall, our results revealed that Spy1 is a necessary
driver of proliferation and stem-like characteristics
in neuroblastoma, particularly in the CD133+ TIC
population. Elevated levels of Spy1 in neuroblastoma
populations suppresses differentiation and promotes TIC
characteristics.

DISCUSSION
Inappropriate differentiation of immature cells
within the ganglionic lineage is thought to drive
neuroblastoma [2-4]. Indeed, the heterogeneous
populations of diverse progenitor cells, seen to exist
within the tumour mirror, neural crest plasticity [12-14].
Multiple studies over the years have attempted to elucidate
the molecular basis behind the differentiation processes
of neuroblastoma. Diverse agents, growth factors and
differentiation protocols have been proposed [43-46];
however, the information about the role of the cell cycle
control in neuroblastoma remains insufficient. We report
for the first time that an atypical G1 phase regulator,
Spy1, is implicated in differentiation and self-renewal of
neuroblastoma cells.
We utilized the SH-SY5Y cell line of an established
N-cell phenotype that is blocked at the precursor stage
of neuronal development. We find that endogenous
Spy1 levels are reduced during cell differentiation and
www.impactjournals.com/oncoscience
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Figure 6: Clonal properties of CD133+ populations of neuroblastoma depend on Spy1. (A) CHLA-15 cells sorted for

CD133. Expression levels of CD133 depicted in CD133+ vs. CD133- population. (B) CD133- and CD133+ populations analyzed for the
number and size of spheres formed. (C; left) Spy1 mRNA levels in CD133- cells subjected to Spy1 overexpression. (C; right) CD133+
population subjected to knockdown control (pLKO-scrambled) or Spy1 knockdown (pLKO-shSpy1 #1 and #2). (D) Number and size
of tumorspheres formed in CD133- cells overexpressing Spy1 (left) or CD133+ Spy1 knockdown cells (right). (E) CD133- population
overexpressing Spy1 assessed for expression of CD133, Ki67 or c-MYC. All genes are expressed relative to GAPDH and pEIZ-Control(cntl)
genes are normalized to 1. pEIZ-Spy1 expression is shown relative to pEIZ-Control. (F) Ki67 (left) and MYC (right) expression in CD133+
cells expressing pLKO-shSpy1#1, pLKO-shSpy1#2 or pLKO-scrambled. (A-F) Data is expressed as mean ±s.d. of triplicates from three
independent experiments, *p < 0.05, **p < 0.01, ***p<0.001 (Student’s t-test).
www.impactjournals.com/oncoscience
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show for the first time that the proliferation and clonal
expansion of CD133+ neuroblastoma TICs relies on
Spy1, and that Spy1 overexpression increases while
its knockdown leads to decrease in c-MYC expression
levels in this population. Consistently our results show
that c-myc protein levels correlate with Spy1 expression
in all neuroblastoma cell lines tested. We have reported
previously that Spy1 expression is regulated downstream
of c-myc [32]. Whether c-myc regulation takes place in
neuroblastoma requires further investigation. These data
support a potential role for Spy1 in maintaining stemlike TIC population in neuroblastoma. Careful analysis is
required to determine if Spy1 manipulation affects specific
subpopulations differently.

Cell pellets were lysed in 0.1% NP-40 lysis buffer (0.1%
NP-40, 20 mM Tris pH 7.5, 5 mM EDTA pH 8.0, 100
mM sodium chloride) for 1 hour, with mixing every 10
minutes. Samples were centrifuged again at 13,000 rpm
for 15 minutes at 4°C to remove cell debris, and stored
at –20°C until use. Imaging was done on the AxioSkope2
Plus microscope (Zeiss) using Northern Eclipse computer
software.

BrdU assay and fluorescent detection
SH-SY5Y cells were grown on cover slips in 60 mm
culture dishes. Over a differentiation time course BrdU
(Cat# 550891; BD Sciences) was added to the media to
a final concentration of 10 µM, incubated for 30 minutes
and then cover slips were harvested. The cell culture
density never exceeded 2x106 cells/ml. Cells were fixed
with 70% ethanol for 30 minutes at room temperature
followed by incubation with 0.07N NaOH for 2 minutes
and neutralization in PBS, pH 8,5. Primary antibody
against BrdU (Cat# 347580, BD Sciences) was applied
for 30 minutes in humidified chamber. The cells were
washed 3 times with PBS and incubated with secondary
antibody conjugated to Alexa- 488 fluorophore (A11059,
Invitrogen) for 30 minutes at room temperature. Cell
nuclei were labeled with Propidium Iodide (0.04 µg/ml)
for 1 minute. Cover slips were washed with water and
mounted on microscope slides with Vectashield mounting
medium. Imaging was conducted on Eclipse E800
microscope (Nikon, Japan)

METHODS
Cell lines
Using BBS/CaCl2 delivery (pH 7.05, 37°C and 3%
CO2) PT67 packaging cells were transiently transfected
with the DNA construct of choice. Following an 8 hour
incubation (37°C and 3% CO2) media was changed, and
cells were allowed to recover at 37°C and 5% CO2. 24
hours later cell media containing the virus were harvested,
centrifuged for 5 minutes at 2,000 g and filter sterilized
using a 0.45 µm filter. An overnight amplification (P2)
was also collected, filter sterilized and stored at -80°C.
Cells were infected with P2 virus at ~70-80% confluency
and incubated overnight in 1:2 volume/volume virus to
cell media ratio containing polybrene (25 µg/ml). Media
was changed the next day and 24 hours later infected
cells were selected in media containing 600 µg of G418.
Individual colonies, as well as mixed populations of
cells, were maintained and the incorporation of cDNA
was checked using genomic DNA and primers spanning
the exon-exon junctions. SH-SY5Y cells were obtained
from ATCC. Stable SH-SY5Y lines were selected and
cells were maintained in media containing 200 µg/mL of
G418. CHLA-15 and CHLA-20 cell lines were obtained
from Children Oncology Group repository (University
of Texas). Infected cells were selected with 1ug/ml of
Puromycin.

Proliferation kinetics
Cells were seeded at the density of 0.5 x104 cells/
ml in 6 well plates or at the density 1.6 x105/ml in 6 cm
tissue culture dishes. The medium and growth factors
were changed daily and proliferation kinetics was
determined by cell counting at the indicated time points
using hemocytometer or TC100 Automated Cell Counter
(BioRad).

MTT assay
Primary, secondary and tertiary neurospheres were
dissociated and 104 cells were seeded in 100 µl of media
in 96 well anti adhesive plates. 20 µl of 5 mg/ml MTT
solution in PBS were added to each well and incubated
for 4 hours. 100 µl of extraction buffer was added for 2
hours to dissolve the formazan crystals and the absorbance
at 590 nm was assessed using Victor plate reader (Perkin
Elmer).

Differentiation assays
SH-SY5Y cells were grown on 60 mm or 100 mm
plates to 60% confluency. 13-cis- Retinoic Acid (2 µM)
was added to SH-SY5Y growth media to induce neurite
outgrowth. Cover-slips and cell pellets were harvested
each day, and control samples (kept in growth media) were
harvested on day 1. Cells were pelleted by centrifugation
at 13,000 rpm for 15 minutes at 4°C, supernatant was
removed, and pellets were stored at –20°C until use.
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Neurosphere formation assay

Immunoprecipitation and CDK2 kinase assay

Cells were seeded into Ultra Low Cluster Plates
(Corning Life Sciences, cat. no.3471) at 5x104 (SHSY5Y; 6-well dishes) or 2x104 (CHLA-15 and CHLA20: 24-well dishes). The serum-free culture medium
DMEM/F12 (Sigma) was supplemented with 60 µM
putrescin, 20 nM progesterone, 5 µg/ml insulin, 100
µg/ml transferrin, 30 nM sodium selenite and 6 µg/ml
glucose. Growth factors: human Epidermal Growth Factor
(Gibco) and basic Fibroblast Growth Factor (Sigma) were
added every 48-72 hours in final concentration of 20 ng/
ml and 10 ng/ml in media, respectively. Differentiation
of primary neurospheres was obtained as described
previously [31]. Neurospheres were transferred on PolyD-Lysine coated cover-slips placed in 6 well plates and
allowed to attach overnight in a drop of culture medium.
To induce differentiation wells were filled with culture
medium supplemented with 2% FBS. After 7-14 days the
cover-slips were examined for neural differentiation and
subjected to immunocytochemistry. To study secondary
neurosphere formation, cells were seeded into 24 or 96well plates at 102 cells per well. After 6-7 days the number
and size of the neurospheres formed were recorded. The
neurosphere diameter was assessed optically with an
object micrometer.

Bradford assays were performed to ensure
equal protein loading, and 100-250 µg of protein was
immunoprecipitated from SH-SY5Y cell lysates. Protein
was incubated with 5 µL of CDK2-mouse antibody
overnight at 4°C. The following day, 5 µL of protein A
sepharose beads were added to the samples and incubated
for 1 hour at 4°C. Samples were then washed three times
with NP-40 lysis buffer at 4°C and aspirated to a final
volume of 25µl. CDK2 kinase assays were performed in
kinase buffer (50 mMTris-Hcl pH 7.5, 10 mM MgCl2, 1
mM DTT, 20 mM EGTA) and 0.5 µCi/µL [γ-32P]ATP~3,000 Ci/mmol obtained from Perkin Elmer. 4 µg of
Histone H1 was added to each 25 µl immunoprecipitated
sample (described above) incubated with 25 µL of 2
times kinase buffer. Samples were incubated at 30°C
for 30 minutes, followed by the addition of 25 µL of 4
times sample buffer. Samples were boiled for 5 minutes
at 95-105°C and loaded onto 10% polyacrylamide gels.
SDS-PAGE and transfer were performed as described
above. Membranes were exposed using a Cyclone
PlusPhosphoimager (Perkin Elmer), and analyzed using
OptiQuant software.

qRT-PCR

Western blotting

Total RNA was extracted from cells or tissues
utilizing RNAeasyPlus Mini Kit (Qiagen) and reverse
transcribed using 200U Superscript II (Invitrogen), 0.5
µg OligodT’s and 0.5 µg random nanomers (Sigma)
according to the manufacturer instructions. For each
experiment the samples were reverse transcribed at the
same time and cDNA was stored at -20oC. Real time
PCR with SYBR green (Applied Biosystems) fluorescent
detection and 200-250 nM of each primer was performed
using ABI Prism 7300 or Viia7 thermocycler. Primers
were designed using Primer Express software. GAPDH
was used as the endogenous control. Data was analyzed
using ABI 7300 or Viia7 software and represented as log10
relative quantification (RQ) or RQ relative to control.

Protein samples were prepared with 4 times sample
buffer (10% glycerol, 62.5 mM Tris-HCl pH 6.8, 2% SDS,
0.01 mg/mL bromophenol blue, 2% β-mercaptoethanol),
and boiled for 5 minutes at 95-105 °C. Samples were
loaded onto 10% polyacrylamide gels and ran at 110 volts
for 4.5 hours. Proteins were then transferred to PVDF
membranes through semi-wet transfer at 30 volts for 2.5
hours. Membranes were blotted in 3% milk for 2 hours to
overnight. Primary antibodies were incubated overnight at
4°C (except for Actin mouse, which was incubated 1 hour
at room temperature). Antibody concentrations used were
as follows: Actin MAB150 1R, (Chemicon- Millipore;
1:1000), -Tubulin TU-02 (Sigma; 1:1000), CDK2 mouse
D-12 (Sigma 1:1000), CDK2 rabbit M2 (Sigma; 1:500),
human Spy1 (Novus; 1:1000-1:10000, Abcam; 1:1000),
p27Kip1 NA35 (Calbiochem 1:100), GAP43 G9264 (Sigma
1:1000), GFAP G4546 (Sigma 1:1000), Nestin G-20
(Santa Cruz 1:1000). Membranes were washed with TBST
3 times for 5-10 minutes, followed by 1 hour incubation
in secondary antibody (mouse, rabbit or goat – 1:10000)
at room temperature. Membranes were then washed with
TBST 3 times for 15 minutes and were visualized using
FluorChemHD2imaging system (Alpha Innotech).
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